Clinical Trial Results:
A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis
Summary
|
|
EudraCT number |
2013-002351-15 |
Trial protocol |
EE LV BG HU ES PT AT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 May 2022
|
First version publication date |
05 May 2022
|
Other versions |
|
Summary report(s) |
2013-002351-15_EudraCT Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.